BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25596342)

  • 1. The impairment of cholesterol metabolism in Huntington disease.
    Leoni V; Caccia C
    Biochim Biophys Acta; 2015 Aug; 1851(8):1095-105. PubMed ID: 25596342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of cholesterol metabolism in Huntington's disease.
    Leoni V; Caccia C
    Biochem Biophys Res Commun; 2014 Apr; 446(3):697-701. PubMed ID: 24525128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation.
    Carroll JB; Deik A; Fossale E; Weston RM; Guide JR; Arjomand J; Kwak S; Clish CB; MacDonald ME
    PLoS One; 2015; 10(8):e0134465. PubMed ID: 26295712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Huntington's disease: cellular and molecular basis of pathology].
    Korzhova VV; Artamonov DN; Vlasova OL; Bezprozvannyĭ IB
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2014; 64(4):359-75. PubMed ID: 25723022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
    Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
    Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
    J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective degeneration in YAC mouse models of Huntington disease.
    Van Raamsdonk JM; Warby SC; Hayden MR
    Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
    Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
    Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
    Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
    Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole body cholesterol metabolism is impaired in Huntington's disease.
    Leoni V; Mariotti C; Nanetti L; Salvatore E; Squitieri F; Bentivoglio AR; Bandettini di Poggio M; Piacentini S; Monza D; Valenza M; Cattaneo E; Di Donato S
    Neurosci Lett; 2011 May; 494(3):245-9. PubMed ID: 21406216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
    Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
    Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
    Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
    J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxysterols as biomarkers in neurodegenerative diseases.
    Leoni V; Caccia C
    Chem Phys Lipids; 2011 Sep; 164(6):515-24. PubMed ID: 21515244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells.
    Ribeiro M; Rosenstock TR; Cunha-Oliveira T; Ferreira IL; Oliveira CR; Rego AC
    Free Radic Biol Med; 2012 Nov; 53(10):1857-67. PubMed ID: 22982598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury.
    Cartagena CM; Burns MP; Rebeck GW
    Brain Res; 2010 Mar; 1319():1-12. PubMed ID: 20053345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington's disease.
    Roze E; Bonnet C; Betuing S; Caboche J
    Adv Exp Med Biol; 2010; 685():45-63. PubMed ID: 20687494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death.
    Roze E; Betuing S; Deyts C; Marcon E; Brami-Cherrier K; Pagès C; Humbert S; Mérienne K; Caboche J
    FASEB J; 2008 Apr; 22(4):1083-93. PubMed ID: 18029446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntington disease: pathogenesis and treatment.
    Dayalu P; Albin RL
    Neurol Clin; 2015 Feb; 33(1):101-14. PubMed ID: 25432725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.